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Abstract
This study seeks to provide evidence for deciding whether or not a new pharmaceutical should
be included in the benefit list of social health insurance. A discrete-choice experiment (DCE)
was conducted in Germany to measure preferences for modern insulin therapy using long-acting
insulin analogue ”insulin detemir” in comparison to NPH insulin. The DCE contains two price
attributes, copayment and increased contributions to health insurance. Of the 1,100 individ-
uals interviewed in 2007, 200 suffered from type 1, 150 from insulin-treated type 2, and 150
from insulin-naive type 2 diabetes. This allows to compare ex-ante and ex-post willingness-
to-pay (WTP). Non-diabetics and insulin-naive diabetics exhibit higher WTP values through
copayment, while affected type 1 and insulin-treated type 2 diabetics have higher WTP through
increased contributions. However, WTP values exceed the extra treatment cost in both financ-
ing alternatives, justifying inclusion of the new drug in the benefit list from a cost-benefit point
of view.
JEL-Classification: I11, H51, I18
Keywords: Health insurance, Discrete-choice experiment, preferences, diabetes
1 Introduction
Health care expenditure (HCE) and especially pharmaceutical expenditure is rising in almost
all developed countries. For example, in the United States the share of pharmaceutical ex-
penditures in total HCE increased from 9 % in 1996 to 12 % in 2007 (OECD (2010)). In an
attempt to curb this surge, several countries have introduced a cost-effectiveness standard for
new pharmaceuticals. This led to the creation of the Medicare Payment Advisory Commis-
sion (MEOPAC) scheme in Australia, the National Institute for Clinical Excellence (NICE) in
the United Kingdom, and the Institute for Quality and Efficiency in Health Care (IQWIG) in
Germany. In Germany, the pharmaceutical bill paid for by statutory health insurance (GKV)
increased from e22 billion in 2004 to e26 billion in 2007, or from 1.00 % of GDP to 1.07 %
(Statistical Offices of the La¨nder (2009)). Before 2007, pharmaceutical innovations had to meet
safety and efficacy benchmarks to be included in the GKV list of benefits. Now, they also have
to be cost-effective.
This study seeks to provide evidence for deciding whether or not a new pharmaceutical for
insulin therapy, a long-acting insulin analogue12 should be included in the German benefit list
of social health insurance. So far, the standard of treatment has been Neutral Protamine Hage-
dorn (NPH) insulin which is human insulin. The new pharmaceutical promises several medical
advantages, such as fewer events of hypoglycemia, less weight gain (or even weight loss), easier
preparation, and more flexibility in injection time (for a list of references on clinical outcomes
studies, see Section 3 below). These potential advantages come with an average cost of e226 per
year and diabetic (in Germany). Concerning the cost-effectiveness of insulin analogues compared
to NPH insulin, there have been several studies presenting mixed, but mostly positive results.
Whereas e.g. Caermon & Bennett (2009) find the pharmaceutical not to be cost-effective, other
studies disagree, e.g. Valentine et al. (2007) for type 2 diabetics3 in the United States.
There are two reasons why this preparation is of special interest. First, diabetes prevalence is
higher then ever in industrialized countries and continues to increase rapidly. The World Health
Organization (WHO) projects the number of diabetics worldwide to rise from 170 million in
2000 to 360 million by 2030 (World Health Organization (2007), Wild et al. (2004)). For the
United States Huang et al. (2009) estimate the number of diabetics to increase from 23.7 in 2009
to 44.1 million patients in 2034. Expenditure on diabetes treatment is expected to rise from $
113 billion to $ 336 billion. The prevalence of diabetes in Germany is 4 to 10 % between ages 40
and 59 and 18 to 28 % for ages above 60 (Hauner (2008)). Second, long-acting insulin analogues
may well constitute a test case. IQWIG recommended to drop short-acting insulin analogues
from the benefit list (and will do so most likely for the long-acting variant), judging it not to be
1 The product considered in this paper is ”Insulin detemir” by Novo Nordisk Pharma GmbH.
2 Modern insulin therapy uses long- and short-acting insulin in combination. Whereas rapid-acting insulin
meets insulin need during mealtimes, long-acting insulin assures base-level supply. Both rapid- and long-
acting insulin can be human or insulin analogue. Whereas human insulin is genetically identical to insulin
from the human pancreas, insulin analogue differs slightly to improve the insulin’s properties.
3 In case of type 1 diabetes the body does not produce insulin. It is usually diagnosed in children and young
adults and has to be treated with insulin from the beginning. In type 2 diabetes, either the body does not
produce enough insulin or the cells ignore the insulin. This type is usually diagnosed in the elderly. Diabetics
of type 2 are called ”insulin-naive” if they are not treated with insulin (yet) but with oral anti-diabetics.
However, during the course of their disease they will need insulin treatment as well (American Diabetes
Association (2010)).
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cost-effective (IQWIG (2009a) and IQWIG (2009b)). However, these recommendations did not
take into account preferences of (potential) patients. Several aspects of the drug which may be
innovative from the patient’s perspective were neglected or judged as therapeutically unimpor-
tant. The (potential) patients’ preferences can be elicited in a discrete-choice experiment (DCE).
With the inclusion of a financial attribute, willingness-to-pay (WTP, or willingness-to-accept
(WTA)) values can be attached to the characteristics of the product, permitting to express its
(dis-)utility in terms of money. From the point of view of the insured (comprising both actual
and potential patients), inclusion of the new product in the list of benefits is justified if they
exhibit a WTP that exceeds the extra cost of the treatment.
To the knowledge of the authors, there has been no WTP study concerning long-acting insulin
analogues. This study presents a DCE comparing insulin analogue with NPH insulin conducted
in Germany in the Fall of 2007. Participants in the DCE are 1,110 members of statutory health
insurance GKV, of whom 200 suffer from type 1 diabetes, 150 from insulin-treated type 2 dia-
betes, and 150 from insulin-naive type 2 diabetes. Distinguishing these groups allows to estimate
ex-ante WTP for non-diabetics and insulin-naive diabetics on the one hand and ex-post WTP
for insulin-treated patients on the other. Four attributes describing differences in insulin ther-
apy between NPH insulin and insulin analogue were included according to medical outcomes
studies: Risk of hypoglycemia, weight gain during the first six months of insulin treatment, need
to swing (not shake) the insulin before injections, and flexibility with regard to time of injec-
tion. There are two attributes for the mode of payment, financing through patients themselves
(copayment) and through increased health insurance contributions, respectively. The inclusion
of two financial attributes permits to test whether the new drug has a favorable benefit-cost
ratio regardless of the boosting of WTP caused by health insurance.
There are four main questions to be answered. (1) Is there positive WTP for long-acting in-
sulin analogue by the members of German statutory health insurance? (2) If so, which product
attributes contribute to WTP? (3) Is there preference heterogeneity between non-affected non-
diabetics and insulin-naive type 2 diabetics on the one hand and type 1 diabetics and insulin-
treated type 2 diabetics on the other? (4) Is the benefit-cost ratio of the new drug favorable
regardless of whether it is financed jointly through increased GKV contributions or by patients
through copayment?
This paper is organized as follows. Section 2 gives an overview of cost-effectiveness studies con-
cerning insulin analogue and of preference studies regarding insulin therapy. Section 3 presents
the interview strategy and questionnaire design with the attributes and levels. Then theory
behind DCEs is briefly presented in Section 4 with emphasis on the difference between ex-ante
and ex-post WTP measurement. Hypotheses are formulated in Section 5 before presenting de-
scriptive statistics in Section 6. Section 7 contains the empirical evidence and hypothesis tests.
The four questions raised are answered in the concluding Section 8.
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2 Literature Review
Cost-Effectiveness Studies
Existing cost-effectiveness studies of the insulin analogue use quality-adjusted life years (QALYs)
as the benefit measure and the incremental cost effectiveness ratio (ICER) as the valuation cri-
teria. Until recently, they focused on the treatment of type 1 patients. For the UK, Palmer et al.
(2004) and Palmer et al. (2007) find improvements of 0.09 and 0.66 QALYs, resulting in ICER
of £19,285 and £2,500, respectively, which compare favorable with the ICER of £30,000 used
by NICE. These estimates are confirmed by Palmer et al. (2008) for Denmark with an ICER
of kr55,867 or £6,600. In their multi-country study, Gschwend et al. (2009) conclude that the
insulin analogue is likely to be a dominant treatment strategy for type 1 patients in Belgium,
Germany, and Spain, and highly cost-effective in France and Italy with an ICER of e519 and
e3,256 per QALY, respectively. For the United States, Leichter (2008) found the pharmaceuti-
cal to be cost-effective due to lower incidence of acute hypoglycemic events and costly, chronic
complications such as nephropathy. In the same vein, Valentine et al. (2006) estimate a ICER
of $ 14,974. With regard to type 2 patients the findings are slightly more mixed. While Valen-
tine et al. (2007) estimate an even lower ICER of $ 6,269 than for type 1 patients, Caermon
& Bennett (2009) arrive at $ 387,729, leading them to conclude that long-acting analogues are
unlikely to present an efficient use of health care resources.
WTP Studies
For all its popularity, the cost-effectiveness measures is not satisfactory from an economic point
of view for two main reasons. First, QALYs focus exclusively on health outcomes, neglecting
attributes of the treatment process such as fear, isolation, and confinement. Second, this mea-
sure does not allow to pit resources devoted to health against resources devoted to other uses.
Specifically, it fails to reflect the preferences of citizens who may favor an expansion of the health
budget, with the consequence that the threshold ICER value (e.g. the £30,000/QALY applied
by NICE) could be adjusted upward. By way of contrast, measurement of WTP values permits
to compare marginal benefit to marginal cost, both expressed in money.
The first WTP study concerning insulin therapy is Davey et al. (1998) in Australia. The authors
compared insulin lispro, the first rapid-acting insulin analogue, with neutral (regular) insulin
using a contingent-valuation approach. Respondents first were presented with the descriptions
of two types of insulins and had to choose one. Then, they were taken through a series of ”bid-
up” questions to determine their maximum WTP. The sample consisted of both type 1 and type
2 diabetics who had been treated with insulin before. The same method was applied by Dranit-
saris et al. (2000) to elicit WTP for the rapid-acting insulin analogue Humalog Mix 25. Unlike
the first study, the sample was drawn from the general tax-paying public. Sadri et al. (2005)
analyzed WTP for inhaled insulin, using the payment scale method. The study involved type 1
and type 2 diabetics and presented results both for insulin-naive and insulin-dependent patients.
In contrast to the contingent-valuation approach, the levels of all attributes characterizing the
alternative are allowed to change in a DCE, which makes participants repeatedly choose between
the status quo and an alternative. The first DCE study concerning insulin therapy is Aristides
et al. (2004) who compared Humalog Mix 25, an insulin analogue, with rapid-acting human
insulin Humulin 30/70 and found significant WTP in five European countries. Hauber et al.
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(2009) elicited preferences in a DCE for oral diabetes treatment in type 2 patients through
a web-enabled survey. Special emphasis was on causes for non-adherence. Guimara˜es et al.
(2009a) and Guimara˜es et al. (2009b) investigated preferences for oral versus injectable insulin
therapy in a DCE. They found that once the psychological barrier to initiating insulin therapy
had been overcome, patients accommodated and accepted injectable therapy as a treatment
option.
3 The Experiment
Sample and Interview Strategy
This DCE was conducted in Germany in the Fall of 2007. Because one of the research questions
is whether financing insulin analogue through contributions to statutory health insurance GKV
or through copayment makes a difference in terms of preferences, only adult GKV members
(some 90 % of the population) were asked to participate. A professional market reserach insti-
tute specialized in health care issues was commissioned to recruit individuals and to perform
the interviews, which were face-to-face by trained field investigators. Interviewers found par-
ticipants mainly through their private contacts with people regularly taking part in surveys.
Out of the total 1,110 respondents, 602 do not suffer from diabetes, 202 suffer from type 1, and
306 from type 2 diabetes. Within the type 2 diabetics group, a distinction is made between
insulin-naive and insulin-treated patients (152 and 154 respondents, respectively). Diabetics are
oversampled to be able to study heterogeneity in preferences. While the sample design allocated
the non-diabetics randomly across the 12 La¨nder (states), ages, and gender, it distributed the
type 2 diabetics equally over the three age groups, 46-55, 56-65, and over 65 because type 2
diabetes occurs almost exclusively past age 45. The minimum duration of diabetes treatment
(insulin injections or oral therapy) was six months. Because it is very difficult to find patients
suffering from type 1 diabetes, randomization was limited to the 12 La¨nder in this case.
Questionnaire
The questionnaire is divided into four parts.
Part 1: The interview begins with questions about the respondent’s health (general health sta-
tus, regular consumption of pharmaceuticals, chronic illness, diabetes, body mass index) and
health insurance (such as yearly contribution or supplementary insurance). This part is the
same for all participants.
Part 2: The remaining survey distinguishes between non-diabetics, insulin-treated diabetics,
and insulin-naive diabetics. For non-diabetics it contains detailed information about diabetes
and its treatment. Respondents are asked to indicate their (subjective) probability of becom-
ing insulin-dependent during their lifetime (using a visual analog scale). Patients treated with
insulin are asked about the course of their disease, their insulin treatment, and its side effects.
Insulin-naive patients are presented with information about diabetes and its treatment as well.
They are asked how long they have suffered from diabetes, their treatment, and side effects.
They are made to indicate their (subjective) lifetime probability of depending on insulin (again
using a visual analog scale).
Part 3: This part is the same for all participants. To prepare them for the DCE, the attributes
are explained in detail, with special emphasis on the two payment vehicles ”copayment” and
”increase in contribution to health insurance”. Since the interviews were face-to-face, respon-
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dents had the possibility to ask questions and interviewers, to offer more explanation. Then,
the insulin used in current therapy is described to respondents (status quo card). Eight times
(see below), an alternative type of insulin with changed attribute levels (alternative card) was
presented and respondents asked to choose between the alternative and the status quo.
Part 4: The interview finishes with socioeconomic items (gender, age, education, and residence).
The last question is monthly household income to be indicated on a visual analog scale to ensure
a high response rate.
Attributes
Although both rapid- and long-acting insulin is required for successful therapy, this study only
considers long-acting insulin. Current treatment guidelines use long-acting NPH insulin to pro-
vide base-level supply. This therapy constitutes the fixed status quo. It is defined by four
attributes, which serve to reflect the differences in the properties of long-acting NPH insulin
and insulin analogue. In contradistinction to other DCEs, no pretest was therefore necessary to
establish the relevant attributes. They are the following.
Risk of hypoglycemia (Hypo, see Table 1) is one of the main side effects of insulin therapy.
Its incidence depends on the individual, the dose of insulin needed, individual habits, and the
insulin preparation. On average the number of hypoglycemic events can be estimated at 1 to
2 per week (Sreenan et al. (2008) and discussions with diabetologists). With a time horizon of
up to six months (see weight attribute below), this puts the risk at 100 percent in the status
quo. Most studies suggest that incidence is lower with insulin analogue than with NPH in-
sulin (see Russell-Jones et al. (2004), Vague et al. (2002), Hermansen et al. (2004), Home et al.
(2004), Kolendorf et al. (2004), Robertson et al. (2004), Russell-Jones (2007), Dornhorst et al.
(2008), Marre et al. (2009) and for meta-analyses Raskin (2007), Satish & Ramachandra (2008),
Demssie et al. (2009), Freeman (2009), Hermansen et al. (2009), and Monami et al. (2009)). A
study that does not find any differences in the frequency of hypoglycemia compared to NPH
insulin is Umpierrez et al. (2009), while Singh et al. (2009) report mixed results. A Cochrane
review (Horvath et al. (2007)) concluded fewer analogue users experienced symptomatic overall
or nocturnal hypoglycemic episodes compared to NPH insulin users. The magnitude of the
decrease varies across studies. Hermansen et al. (2009) found a reduction of total hypoglycemic
events of over 50 %, Kolendorf et al. (2004) of 18 %, and Vague et al. (2002) of 22 %. IQWIG
wrote in its final report (IQWIG (2009c)) that insulin analogue significantly lowers the risk of
severe (analogue: 0.0 % vs. NPH: 2.1 %), of mild (analogue: 57.0 % vs. NPH: 78.2 %, OR
= 0.37) and of nocturnal hypoglycemia (analogue: 26.2 % vs. NPH: 44.1 %, OR = 0.45) for
type 2 diabetes (for type 1 patients there is no final report yet). A conservative value of 30
% risk reduction is therefore attributed to insulin analogue. In order to have sufficient spread
for statistical inference, the alternative incidence levels are set to 75 and 50 % relative to NPH
insulin in the DCE.
Obesity (Weight) is a major problem of type 2 diabetes patients. 80 % suffer from obesity
according to Russell-Jones & Khan (2007). Correspondingly, Ha¨ussler et al. (2005) found a
significantly higher Body Mass Index (BMI) in type 2 patients than in the overall German
population. Insulin therapy makes this problem even worse. As a side effect of treatment with
human insulin, patients gain weight, especially during the first months of insulin therapy. The
UK Prospective Diabetes Study (UKPDS) Group (1998) observed a 2.5 kg increase over 6 months
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Table 1: Product attributes and levels
Attribute Label Status quo Alternatives
Overall risk Hypo 100 % 100% / 75% / 50%
of hypoglycemia
Weight change Weight + 2,5 kg + 2.5 kg / ± 0 kg / – 1.0 kg
Swinging Swing Necessary Necessary / Not necessary
Time of injection Flexibility Predetermined Predetermined / Not predetermined
Copayment Copayment None None / e50 / e150 / e300∗
Health insurance Contribution None None / +0.5% / +1.0% / +2.0%
contribution
∗ e1 = $ 1.25 at 2008 exchange rates.
on average; this value serves to describe the status quo. Insulin analogue is found to mitigate
weight gain (see Haak et al. (2003), Haak et al. (2005), Hermansen & Davies (2007), Raslova´
et al. (2007), Russell-Jones & Khan (2007), Dornhorst et al. (2008), Demssie et al. (2009), Free-
man (2009), Mandosi et al. (2009), Marre et al. (2009), Monami et al. (2009)). It may even
cause weight loss of up to 1 kg (Russell-Jones (2007), Sreenan et al. (2008), Hermansen et al.
(2009), for meta-analyses see Bush (2007), Raskin (2007), and Satish & Ramachandra (2008)).
The evidence allows to associate insulin analogue with a weight gain of 0 kg, while the levels
used in the DCE are + 2.5, 0, and - 1 kg, respectively.
Before every injection, human NPH insulin has to be swung (not shaken) to achieve uniform
dilution (Swing), ensuring injection of an optimal amount of insulin. This defines the status
quo (see Table 1). Insufficient swinging causes a risk of injecting a suboptimal amount of insulin
and inadequate control of blood sugar levels (Schleser-Mohr (2007)). Insulin analogue can be
injected immediately, without swinging (Schmeisl (2009)). These two levels also appear in the
DCE.
Another difference in the two types of insulin is flexibility with regard to time of injection
(Flexibility, see Table 1 again). Human insulin reaches its maximum effect often after a few
hours (Soran & Younis (2006)). The time of the bedtime injection therefore is set at 10 pm to
avoid insufficient insulin levels in the early morning; this defines the status quo. Insulin analogue
has a different action profile. Its maximum effect occurs later (see Kurtzhals (2007) and Demssie
et al. (2009)), allowing patients to inject insulin already before 10 pm, usually between dinner
and bedtime. However, time of injection should not vary from day to day. Insulin analogue is
therefore described accordingly, and this attribute again has two levels in the DCE.
The last two attributes listed in Table 1 describe two modes of financing, individually through
copayment by diabetics themselves or collectively through increased GKV contributions by the
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whole population. Inclusion of these two price attributes can be justified for at least three rea-
sons. First, Germany has been introducing copayment on pharmaceuticals along with reference
pricing of drugs, making it a mode of financing of increasing importance. Second, a population
may well have preferences with regard to modes of financing, as evidenced by Skjoldborg &
Gyrd-Hansen (2003) for the case of Denmark. And third, economic considerations lead one
to suspect that those affected by the disease prefer financing through increased insurance con-
tributions (which fall on everyone) over copayment (which burdens only the affected). This
hypothesis will be tested (see H4 of Section 5).
As to Copayment, there is none in the status quo for diabetes patients, regardless of type of
therapy (see Table 1). In the alternative, the levels are 50, 150, and e300 per year, respectively.
As to Contribution, respondents were asked to look up the actual amount paid to establish an
individual-specific status quo. Contributions are estimated to increase by e8.54 per year and
GKV member4 if insulin analogue is added to the benefit list. On average this corresponds to
an increase of 0.5 % of annual health insurance contributions, which is the value attributed to
insulin analogue. In the DCE levels characterizing the alternative are set to increases of 0.5, 1,
and 2 %, respectively.
Pretest and Design
The pretest was conducted by the same market research institute and consisted of 30 face-to-
face interviews with individuals from the greater Leipzig area (17 non-diabetics, four type 2
insulin-dependent, four type 2 insulin-naive, and five type 1 patients, 23 women and 7 men, 52
years of age on average). One-third of the interviews were monitored by the authors of this
study. In general, participants and interviewers understood the questions well. 25 individuals
rated the choices ”easy” and five ”difficult”. However, no one rated them ”very difficult”. On
average the new insulin was chosen 3.8 times out of 10 choices. Econometric estimates con-
firmed the relevance of attributes and levels, with one exception. In the pretest, increases in
insurance contributions were 0.25, 0.5, and 1 %. Apparently, this range was not sufficient to
affect decisions. Therefore it was scaled up to 0.5, 1, and 2 %. Figure 1 shows an example of a
choice question.
For the main survey, a D-optimal design was constructed (Street et al. (2001), Burgess & Street
(2003), and Carlsson & Martinsson (2003)), using the software GOSSET (see Kuhfeld et al.
(1994) and Sloane & Hardin (2007)). Out of the 576 possible combinations, 30 were retained in
this way and divided into four card sets. Each set consisted of eight choices between the current
insulin (status quo) and a new insulin (alternative). Consistency was tested by including weakly
dominated alternatives, which however were favored only by a few respondents. ”Expensive”
alternatives were chosen significantly less often than ”cheaper” ones. In total, the new insulin
was picked in 40 %, the current insulin in 60 % of cases. 27 individuals did not alternate between
the current and new insulins. Half of the respondents stated that decisions were ”easy”, 39 %
”difficult”, and 11 % ”very difficult”.
4 On average, extra cost of treatment with insulin analogue rather than human insulin is e226 per year and
diabetic. Multiplied by the number of insulin-treated diabetics in Germany (=1.9 million, see Giani et al.
(2004)) and divided by the number of GKV members paying contributions (=50.471 million, see BMG
(2007)) one obtains e8.54 per year and GKV member.
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Figure 1: Choice question example: Fixed status quo (current insulin) vs. alternative (new
insulin)
Choice Question: Would you prefer insulin-dependent diabetics to 
be treated with the current or the new insulin?
Current Insulin New Insulin
1 Events of hypoglycemia on average 1-2 per week approx. 25% lower risk
2 Weight change during + 2.5kg weight gain
first 6 months of therpay
3 Accuracy of dosage / preparation Before every injection No swinging 
of insulin before every injection swinging necessary necessary
4 Point in time of injection Predetermined: After 10pm Predetermined: After 10pm
(daily identical) (daily identical)
5 Additional copayment per year None 50 Euro
6 Your Contribution to statutory + 0.5%  =  +_____ Euro
health insurance per year
In this situation I choose  □ the current insulin  □ the new insulin
+ 2.5kg weight gain
_____ Euro
4 Ex-ante vs. Ex-post Willingness-To-Pay
Based on random utility theory (see Luce (1959), Manski & Lerman (1977), McFadden (1974),
McFadden (1981) and McFadden (2001)), DCEs are designed to investigate individuals’ prefer-
ences for (non-)marketed goods or goods that do not exist yet.
In a DCE participants are asked repeatedly to choose several times between a fixed status quo
and an alternative whose attributes take on different values each time. When choosing between
alternatives, a rational individual will always select the alternative with the higher level of
expected utility. Neglecting the expectation operator for simplicity, the decision-making process
can thus be seen as a comparison of utility values determined by
Uij ≡ v(aj , pj , yi, si, εij), (1)
where Uij represents the indirect utility value attained by individual i in alternative j. It
depends on the vector of attributes aj , price pj , the individual’s income yi, and socioeconomic
characteristics denoted by si. Finally, εij is an error term that varies over alternatives and
individuals. Provided the error term is additive, the individual will choose alternative k over
alternative l if
u(ak, pk, yi, si) + εik ≥ u(al, pl, yi, si) + εil, (2)
where u(·) is the deterministic component of the utility function v(·). Unlike εij , this compo-
nent can be estimated from observed choice behavior. For this purpose it is assumed that the
probability of choosing the alternative k over l, Pik, equals the probability of the difference in
equation (2) occurring. Solving for the difference in error terms, one obtains
Pik = Prob[εil − εik ≤ u(ak, pk, yi, si)− u(al, pl, yi, si)]. (3)
For any inference about the left-hand side of inequality (3), a probability law for ω=(εil − εik)
must be assumed. Since the logistic distribution assumes independence of irrelevant alternatives
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(IIA), the normal distribution is used here, resulting in probit estimation. It is assumed that
errors are correlated between the choices of a given respondent but not across respondents,
calling for random effects specification. With the utility function linear in parameters (Louviere
et al. (2000)), one has
∆Uik = β0 + β1a1k + β2a2k + . . .+ βLaLk + ωij , (4)
with ωik=µi+νik. Here, a1k, ..., aLk are the attributes of the alternative in consideration.
According to equation (3) only differences in utility matter. Thus, fixed characteristics of re-
spondents drop out. The βs are the parameters to be estimated.
Based on Hanemann (1983), the marginal rate of substitution between two attributes m and n
is equal to the ratio of the derivatives of the indirect utility function with respect to the two
attributes,
MRS =
∂v/∂am
∂v/∂an
=
βm
βn
. (5)
Defining n as a financial attribute allows to interpret the negative of the marginal rate of sub-
stitution as a marginal WTP for attribute m.
A special feature of this study is that it seeks to measure WTP of both individuals who do
not suffer from the disease or do not need insulin yet (ex-ante) and insulin-treated diabetes
patients (ex-post). Whereas the utility gained (or lost) from a change in treatment is a real
and immediate utility change for insulin-treated diabetics, it is an expected utility for non- and
insulin-naive diabetics, which can be written as
EUij = pii · Uij(Therapy|Diabetic) + (1− pii) · Uij(Therapy|Non-Diabetic), (6)
where pii is the individual-specific (subjective) probability to come down with insulin-treated
diabetes. For patients treated with insulin, pii is equal to 1, causing the second term of eq.(6)
to become zero. In this case, eq.(6) is equal to Uij , the individual’s utility experienced form
alternative j. When substituting the attributes described above into eq.(1), and assuming
linearity, utility for insulin-dependent diabetics becomes
Uij = β0 + β1Hypoij + β2Weightij + β3Swingij + β4Flexibilityij (7)
+β5Copaymentij + β6Contributionij + εij .
For individuals not suffering from the disease and insulin-naive diabetics, pii is between zero and
one. Their expected utility function therefore reads,
EUij = pii · (β0 + β1Hypoij + β2Weightij + β3Swingij (8)
+β4Flexibilityij + β5Copaymentij + β6Contributionij)
+(1− pii) · (β0 + β6Contributionij) + ωij
Recall that the variables in eq.(7) represent the differences between the current and the new in-
sulin. For example Hypoij is the probability of suffering from hypoglycemia when treated with
the current insulin minus this probability when treated with the new insulin (NPH insulin).
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Consequently, the values for Hypo, Weight, Swing, Flexibility, and Copayment are set equal
to zero in case of non-diabetics and insulin-naive patients because they do not vary across alter-
natives. However, health insurance contributions do vary since if the pharmaceutical is paid for
by the GKV, every member contributes to the cost of the medications covered, not only patients.
There are two main reasons for a non-diabetic person to derive utility from and hence have a
positive WTP for diabetes treatment, namely altruism and/or buying a call option for better
treatment in case of coming down with the disease. Starting with the latter, the first term of
eq.(8) shows the change in expected utility of a person who envisages coming down with insulin-
dependent diabetes and therefore has positive WTP for a call option on new treatments. The
higher the probability pii, the higher the probability of exercising this option, and the higher
WTP. With regard to altruism, the second term of eq.(8) represents the change in expected
utility of a person who envisages staying healthy. In this case, β0 can be interpreted as WTP
due to altruism. Finally, eq.(8) can be rewritten as
EUij = β0 + piiβ1Hypoij + piiβ2Weightij + piiβ3Swingij (9)
+piiβ4Flexibilityij + piiβ5Copaymentij + β6Contributionij + ωij .
This equation holds for non-diabetics as well as for diabetics. For the latter, pii equals 1 if
treated with insulin, causing eq.(9) and (7) to be identical. The calculation of WTP has to
be modified as well. If the financial attribute (n) is specified to be copayment, eq.(5) holds.
However, if it is GKV contributions, the probability of becoming a diabetic has to be taken into
account,
WTP = −pii ·
βm
β6
. (10)
5 Hypotheses
This section is devoted to the statement of hypotheses concerning WTP values.
Hypothesis H1:
From the GKV members’ point of view, insulin analogue generates an additional
utility compared to human insulin.
Increases in contributions and copayment will always have a negative effect on utility. However,
this hypothesis states that the other attributes generate enough additional utility compared to
human insulin to make its total effect positive.
Hypothesis H2:
WTP values for the attributes are in the following rank order.
H2.1 Decreasing the risk of hypoglycemia has the highest WTP, followed by
avoiding weight gain.
H2.2 WTP for more flexibility with regard to time of injection is considerably
lower than for avoiding weight gain.
H2.3 WTP for no need to swing the preparation before injection is very low,
not significantly different from zero.
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Hypoglycemia is a traumatic experience. Symptoms of hypoglycemia include shakiness, dizzi-
ness, confusion, and difficulty to speak, just to mention a few. Severe hypoglycemia can cause
loss of consciousness and even death. Therefore the highest WTP is expected for a decrease in
this risk, dominating concerns about weight gain. This is supported by Hermansen & Davies
(2007), who found that patients often take a precautionary snack to avoid hypoglycemia, accept-
ing weight gain as the consequence. Further supporting references are Guimara˜es et al. (2009b)
(in the context of oral and inhaled insulin delivery) and Hauber et al. (2009) (in the context of
oral glucose-lowering medications) who conclude that patients of both type 1 and type 2 have a
higher WTP for avoiding hypoglycemia than for avoiding weight gain. In turn, avoiding weight
gain is expected to generate a higher WTP than more flexibility with regard to time of injection.
Aristides et al. (2004) analyzed WTP for flexibility in meal-time insulin injections. Whereas
WTP values are significantly positive, they are lower than for avoiding weight gain as estimated
by Guimara˜es et al. (2009b) and Hauber et al. (2009). Finally, failure to swing the preparation
might be a worry for patients at the beginning of the treatment. With increasing experience
permitting them to save time and effort, WTP for this attribute is predicted to go to zero. Recall
that diabetics participating in the DCE had been subject to the condition for six months or more.
Hypothesis H3:
There is significant heterogeneity of WTP values between diabetics and non-
diabetics and between diabetes subgroups.
The difference in experience with using insulin might be the key reason for heterogeneity in
preferences (as found in Guimara˜es et al. (2009b)). Whereas type 1 and insulin-treated type 2
diabetics have used insulin before, non-diabetics and insulin-naive type 2 diabetics have not. For
instance, they do not know what a hypoglycemic situation feels like and how it can be handled.
Hypothesis H4:
Non-affected respondents and diabetics not treated with insulin prefer financ-
ing through patients themselves in the guise of copayment, whereas insulin-
treated patients prefer financing through health insurance contributions.
Both diabetics and non-diabetics are predicted to have positive WTP for insulin analogue.
However, WTP values of non-diabetics and insulin-naive diabetics are expected to be higher
when financing occurs through copayment by patients themselves than jointly by the whole
population through health insurance contributions. Conversely, WTP values of type 1 and
insulin-dependent type 2 diabetics should be higher when financing occurs jointly through health
insurance contributions.
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6 Data: Descriptive Statistics
Table 2 gives an overview of the sample. Approximately 50 % of the respondents are female.
Average age is higher for type 2 diabetics than for the rest of the sample because this dis-
ease occurs primarily among the elderly (although the number of children suffering from type
2 diabetes has been increasing substantially). Respondents were asked to mark their subjec-
tive health status on a visual analog scale ranging from 0 (very bad health) to 100 (very good
health). Non-diabetics reported the highest average value of 73, insulin-treated type 2 patients
the lowest of 53. On average, type 2 diabetics have the highest BMI with 28 (insulin-treated)
and 27 (insulin-naive), respectively. This matches the findings of the UK Prospective Diabetes
Study (UKPDS) Group (1998) stating that obesity is highly prevalent among type 2 diabetics.
The difference in BMI between type 2 and non-diabetics is statistically significant.
Average net household income is e1,904 per month. Insulin-naive diabetics of type 2 have a
lower income (e1,783) than non-diabetics (e1,975). This difference is in accordance with Ha¨us-
sler et al. (2005) who found a negative correlation between prevalence of type 2 diabetes and
income. Because contributions to statutory health insurance GKV are defined as a percentage
of (labor) income, higher incomes lead to higher contributions. While the function is nonlinear
because the percentage varies between sick funds and regions, non-diabetics do pay higher con-
tributions on average than the others. Some 41 % of them also have at least one supplementary
insurance contract, compared to 30 % for type 1 diabetics and 31 % for insulin-treated diabetics.
This reflects the fact diabetics treated with insulin present high risks to private health insurers
offering supplementary coverage, causing high premiums or exclusion clauses to be applied.
The lower part of Table 2 contains information about duration of illness and incidence of diabetic
complications. Type 1 diabetics on average have been suffering for 17 years from the disease at
the time of the DCE. For type 2 diabetics this value drops to 8 to 9 years. Only 18 % of type 2
diabetes patients with insulin treatment do not suffer from any complication. For insulin-naive
type 2 diabetics, this number is 23 % and for type 1 diabetics, 27 %. High blood pressure is
the most common complication, followed by diabetic neuropathy, diabetic feet, and diabetic
retinopathy. Strokes, hearth attacks, as well as amputations, are most common among type 2
diabetics with insulin therapy.
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Table 2: Descriptive statistics
Variable All respondents Non-diabetics Type 1 diabetics Type 2 diabetics Type 2 diabetics
insulin-treated insulin-naive
n 1,110 602 202 154 152
Socioeconomic variables and health status
Age 51.10 (16.18) 47.70 (16.54) 44.67 (15.17) 61.99 (9.74) 62.11 (9.44)
Female∗ 51.49 52.25 50.49 50.65 50.65
Subjective health status1 66.46 (23.27) 72.56 (22.46) 62.06 (22.63) 53.70 (21.95) 61.33 (20.74)
BMI2 26.17 (4.54) 25.26 (4.16) 26.45 (5.32) 28.18 (4.50) 27.35 (3.98)
Health insurance
Income3 1903.75 (1,014.85) 1,974.55 (1,055.40) 1,814.07 (1,022.41) 1,866.67 (918.88) 1,783.22 (918.07)
GKV contribution4 1,879.60 ( 703.91) 1914.77 ( 727.90) 1,832.82 ( 719.00) 1,894.09 (630.44) 1,787.76 (650.30)
Supplementary insurance∗ 37.03 40.51 30.20 31.17 38.16
Duration of illness and incidence of diabetes complications
Years of illness 17.32 (14.40) 8.60 (5.78) 8.03 (8.21)
Diabetes complication∗ 72.87 81.82 76.97
High blood pressure∗ 43.07 63.64 59.21
Diabetic foot∗ 20.30 30.52 16.45
Diabetic neuropathy∗ 32.67 35.06 27.63
Diabetic retinopathy∗ 10.89 14.94 7.24
Stroke / heart attack∗ 8.91 12.39 5.26
Amputation∗ 1.49 3.90 1.32
∗ In % of the respective subsample
1: Subjective health status, 0 = ”very bad” to 100 = ”very good”
2: Body Mass Index
3: Net per household income per year in e
4: Health insurance contribution per year in e
Standard deviations in parentheses.
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7 Empirical Results
7.1 Willingness-To-Pay
As a first step, it is important to know whether the attributes retained are relevant and have the
expected impacts on utility. Table 3 presents the estimation results of eq.(9). All coefficients
are highly significant and have the expected signs. The positive value of the constant can be
interpreted as follows. If the specification of the utility function had been perfect, then the
difference between the alternative and the status quo would be entirely due to the differences in
attributes. There would be no reason to expect a constant different from zero. However, there
may be individual characteristics not accounted for that give rise to a bias in favor or against
the status quo (Salkeld et al. (2000)). In the present case, the positive constant points to a
preference in favor of the alternative and hence a bias against the status quo.
Table 3: Results of a random-effects probit estimation, aggregate sample
Attribute Expected sign Coefficient z-value Marginal effect
Constant 0.7632 15.77
Hypoglycemia1 + 0.0065 14.07 0.002
Weight2 + 0.1380 13.27 0.051
Swing3 ± 0.2947 8.41 0.108
Flexibility3 + 0.1704 4.94 0.063
Copayment – −0.0055 −39.97 −0.002
Contribution – −0.0047 −5.23 −0.002
σu 0.51
ρ 0.20
1: Decrease of the risk of hypoglycemia
2: Avoiding weight gain
3: Dummy-variable, 0 = status quo, 1 = alternative
Using eqs.(5) and (10), marginal WTP values depending on the mode of financing (copayment
and increase in contributions, respectively) can be estimated. The upper part of Table 4 shows
the results for copayment, the lower, for contributions. According to eq.(10) WTP values for
the latter must be probability-weighted for deriving estimates that apply to GKV members in
general, who would pay increased contributions. Estimates weighted by the average subjective
probability of coming down with insulin-treated diabetes are displayed in the last two columns of
Table 4. Subjective probabilities (pii) were measured in the questionnaire using a visual analog
scale from 0 % (will never become insulin-treated diabetic) to 100 % (will become insulin-treated
diabetic with certainty). For diabetics already treated with insulin, pii is equal to one. The av-
erage value (p¯i) over all respondents is 53 %.
For both modes, preference for the alternative is very high, viz. e262 and e162 per year. In
most DCEs, status quo bias is negative, indicating resistance against change (see e.g. Zweifel
et al. (2007), Telser & Zweifel (2002)). In the case of diabetes treatment, respondents seem to
be willing to pay for a shift away from the status quo.
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Table 4: Marginal WTP for product attributes, aggregate sample
Attribute MWTP Standard error z-value MWTP · p¯i∗
Delta Method4 Bootstrap5
Financing through copayment
Constant 261.50 8.54 9.11 30.62
Hypoglycemia1 1.19 0.09 0.10 13.48
Weight2 25.15 1.90 2.19 13.23
Swing3 53.69 6.34 6.31 8.47
Flexibility3 31.04 6.29 6.37 4.94
Financing through health insurance contribution
Constant 161.75 29.20 41.11 5.54 161.75
Hypoglycemia1 1.39 0.28 0.40 4.87 0.74
Weight2 29.25 5.79 8.80 5.05 15.55
Swing3 62.46 13.87 18.48 4.50 33.21
Flexibility3 36.11 10.20 13.31 3.54 19.20
∗: Except constant
1: Decrease of the risk of hypoglycemia by 1 percentage point
2: Avoiding weight gain
3: Dummy variable, 0 = status quo, 1 = alternative
4: Standard errors calculated using the Delta Method
5: Standard errors calculated using bootstrapping with 1,000 replications
All MWTP values are in eper year, e1 = $ 1.4 $ at 2008 exchange rates.
As to the risk of hypoglycemia, respondents are willing to pay an estimated e1.19 per year for a
1 percentage point reduction through copayment and e1.39 through contributions. The second
amount decreases to e0.74 per year when weighted by average probability p¯i (see lower part of
Table 4). To avoid 1 kg of weight gain, respondents are willing to pay e25 through copayment
or e16 through higher yearly contributions, respectively.
To compare the importance of the attributes, consider a 100 % change. Although unrealistic in
the case of hypoglycemia, it allows to compare WTP directly with the (0,1) attributes. For the
risk of hypoglycemia, a 100 % decrease has an approximate WTP of e119 (copayment) and e139
(contribution), respectively. For fully avoiding the average weight gain of 2.5 kg (see Section 3),
which also amounts to a 100 % change, the WTP value is e63 (= 2.5 · 25.15, copayment) and
e39 (= 2.5 · 15.55, contribution). Hence, regardless of mode of financing, respondents value
lowering the risk of hypoglycemia two times more than avoiding weight gain, corroborating H2.1.
As to WTP for increased flexibility with regard to the timing of the injection, the values amount
to e31 (copayment) and e19 (contribution), respectively. This is much less than the e63 and
e39 for avoiding weight gain, in accordance with H2.2.
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Table 5: WTP for product attributes, aggregate sample
Financing through copayment Financing through contribution
Attribute WTP z-value WTP · p¯i∗ z-value
Constant 261.50 16.29 161.75 5.54
Hypoglycemia1 35.74 13.48 22.20 4.87
Weight2 62.87 13.23 38.88 5.05
Swing3 53.69 8.47 33.21 4.50
Flexibility3 31.04 4.94 19.20 3.54
Total 444.84 275.24
Total net of constant 183.34 113.49
∗: Except constant
1: Decrease of the risk of hypoglycemia by 30 %
2: Avoiding a 2.5 kg weight gain
3: Dummy variable, 0 = status quo, 1 = alternative
All WTP are in eper year.
The possibility to inject insulin without swinging before every injection is worth e54 (copay-
ment) or e33 per year (contribution), respectively. Since these values differ from zero, they con-
stitute evidence against H2.3. A seemingly minor innovation (from the medical point of view) is
clearly valued by consumers. However, it is valued less than avoidance of either hypoglycemia
or weight gain. For instance, the difference between e119 (100 % change in hypoglycemia, co-
payment) and e54 (swing, copayment) has statistical significance in view of the small standard
errors displayed in Table 4.
To test H1 (positive value of the new pharmaceutical) total WTP values need to be calculated.
As described in Section 3, insulin analogue corresponds to the following changes in attributes.
Risk of hypoglycemia decreases by 30 % in comparison to treatment with human insulin NPH.
Whereas patients gain 2.5 kg on average with human insulin, there is no weight change with
insulin analogue. The preparation does not need to be swung, and the timing of injection is
more flexible. Following Hanemann (1983), WTP associated with these non-marginal changes
is computed as the marginal WTP multiplied by the change of the attribute’s value. These
component values are then summed up to obtain total WTP for the product (see Johnson &
Desvousges (1997)). The results of these calculations are shown in Table 5. Total WTP for
the new drug amounts to e445 per year if financed through copayment and e275 (probability-
weighted) if financed through an increase in contributions. Approximately 60 % of this WTP
comes from bias in favor of the alternative. Even if this component is subtracted, the result-
ing values of e183 and e114, respectively, are still significantly positive in view of the small
estimated standard errors displayed in Table 5. Therefore, H1 is confiremd.
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7.2 Willingness-To-Pay across Subgroups
To obtain group-specific WTP values, eq.(9) is estimated separately for non-diabetics, type 1
diabetics, type 2 insulin-naive as well as for insulin-treated diabetics. Group-specific MWTP
values (not shown) are multiplied by the changes in attribute levels due to insulin analogue
and summed, in full analogy to Table 5. The subjective probability of acquiring insulin-treated
diabetes is 26.2 % on average for non-diabetics and 56.4 % for insulin-naive patients. The re-
sulting non-marginal WTP values across subgroups are presented in Table 6. Sum I comprises
all component WTP values, sum II only the significant ones. Standard errors (z-values shown)
are small enough to conclude that there is preference heterogeneity between these four groups,
confirming H3.
Table 6: WTP for product attributes, stratified by diabetes type
Non-Diabetics Diabetics
Type 1 Type 2 Type 2
Insulin-treated Insulin-naive
Attribute WTP z-value WTP z-value WTP z-value WTP z-value
Financing through copayment
Hypoglycemia 38.53∗∗∗ 10.76 27.95∗∗∗ 4.56 29.25∗∗∗ 4.02 43.98∗∗∗ 5.69
Weight 71.80∗∗∗ 11.23 37.49∗∗∗ 3.39 71.53∗∗∗ 5.35 50.16∗∗∗ 3.69
Swing 56.62∗∗∗ 6.67 48.28∗∗∗ 3.28 72.17∗∗∗ 4.03 25.85 1.43
Flexibility 25.22∗∗∗ 3.00 24.37∗ 1.65 50.71∗∗∗ 2.89 46.45∗∗∗ 2.57
Constant 597.47∗∗∗ 13.58 106.90∗∗∗ 5.50 94.62∗∗∗ 4.08 286.55∗∗∗ 6.42
Sum I 789.63 244.99 318.29 452.99
Sum II 789.63 244.99 318.29 427.14
Financing through health insurance contributions
Hypoglycemia 11.32∗∗∗ 3.88 34.11∗ 1.89 100.11 0.63 17.65∗∗∗ 2.51
Weight 21.09∗∗∗ 4.00 45.75∗ 1.88 244.76 0.65 20.13∗∗∗ 2.38
Swing 16.63∗∗∗ 3.55 58.92∗ 1.80 246.97 0.64 10.38 1.28
Flexibility 7.41∗∗ 2.41 29.74 1.28 173.53 0.62 18.64∗ 1.87
Constant 175.51∗∗∗ 4.38 130.46∗∗ 2.20 323.79 0.67 115.00∗∗∗ 2.93
Sum I 231.96 298.99 1089.16 181.80
Sum II 231.96 269.25 0.00 171.43
∗ Significant at the 10 % level, ∗∗ at the 5 % level, and ∗∗∗ at the 1 % level
1: Decrease of the risk of hypoglycemia by 30 percentage point
2: Avoiding a 2.5 kg weight gain
3: Dummy-variable, 0 = status quo, 1 = alternative
4: Only significant values
All WTP values are in eper year.
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Moreover, comparison of the upper and the lower part of Table 6 shows that the mode of pay-
ment matters, but not entirely in the way predicted by H4. As stated by H4, WTP values among
diabetics should be higher when the new pharmaceutical is financed through increased GKV
contributions rather than copayment, while among the non-affected, it should be the other way
round. Now non-diabetics indeed exhibit a higher total WTP value when financing is through
copayment. They are joined by the insulin-naive diabetics who apparently deem themselves
not to be affected. On the other hand, type 1 diabetics do have higher WTP when financing
occurs through increased contributions, but the difference is not statistically significant. For
insulin-treated type 2 diabetics, the ordering is as expected at first sight (sum I). Their WTP
is extremely high when they envisage financing through increased contributions rather than
copayment. However, not a single component value is significantly different from zero, causing
sum II to be zero as well. Apparently, opinions concerning insulin analogue are very divided
among these patients as soon as it were to be paid for by increased contributions.
The high WTP values estimated for non-diabetics in the case of copayment also merit discussion.
It is doubtful that they would be verified in a real purchase decision. Rather, being importantly
due to a high constant, they point to a strong bias in favor of the alternative - provided those
affected pay for the new drug themselves.
Finally, the entries of Table 6 can also be interpreted in the following way. The high copayment-
related WTP values of non-diabetics and insulin-naive diabetics suggest that they prefer financ-
ing through patients themselves. Conversely, insulin-treated patients prefer financing jointly
through health insurance contributions. However, whatever the group considered and regardless
of mode of payment, WTP for insulin analogue measured by Sum I exceeds its cost of treatment
(estimated at e226 per year). If measured by Sum II, this is also true, with the only excep-
tion of type 2 insulin-treated patients whose preferences are too heterogeneous. Therefore, by
a benefit-cost criterion, including this product in the GKV list of benefits appears to be justified.
8 Conclusions
This study revolves around the issue of whether a particular new pharmaceutical should be
included in the benefit list of a social health insurer. From a cost-benefit perspective and ne-
glecting distributional concerns, inclusion is justified if the insured have a willingness-to-pay
(WTP) that exceeds the cost of treatment with the new product. The case in question is mod-
ern insulin therapy, using the long-acting insulin analogue ”insulin detemir”. Preferences for
this preparation in comparison to conventional therapy (using human insulin) are derived with
the help of a discrete-choice experiment. It involved 1,110 members of German statuary health
insurance (GKV) in 2007, of whom 202 suffer from type 1 diabetes, 154 from type 2 diabetes
treated with insulin, 152 are insulin-naive type 2 diabetics, and 602 are non-diabetics. The nov-
elty of the experiment lies in two aspects. First, distinguishing these groups allows to estimate
both ex-ante WTP for non-diabetics and ex-post WTP for diabetic patients. Second, including
the mode of payment (copayment vs. increased GKV contribution) permits to test whether the
new drug has a favorable benefit-cost ratio regardless of the way it is financed. Based on the
results reported in the text, four research questions can be answered.
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(1) Is there positive WTP for the long-acting insulin analogue? The evidence suggests there is,
compared to the conventional therapy using long-acting human insulin NPH (Table 5). Compo-
nents of this total value are WTP for reduction of the risk of hypoglycemia by 30 %, no weight
gain rather than 2.5 kg during the first six months of the therapy, relief from the need to swing
the preparation before each injection, and flexibility with regard to the timing of the injection.
(2) Which product attributes contribute to total WTP? All product attributes have positive
estimated WTP values. For comparison purposes, a hypothetical 100 % reduction of the risk
of hypoglycemia and of the weight gain are considered because the other attributes are (0,1)
variables. In accordance with expectations, the maximum WTP value comes from risk reduction
with respect to hypoglycemia, followed by avoiding weight gain. The other attributes are less
highly valued, as predicted.
(3) Is there preference heterogeneity across morbidity groups, viz. non-diabetics, type 1 diabet-
ics, insulin-treated type 2 diabetics, and insulin-naive type 2 diabetics? Estimates do point to
heterogeneity. Total WTP values differ significantly between subgroups. Non-affected insulin-
naive type 2 and non-diabetics have similar preferences, as do affected type 1 and insulin-treated
type 2 diabetics.
(4) Is the benefit-cost ratio of the new pharmaceutical favorable regardless of whether it is
financed jointly through increased GKV contributions or by patients themselves through copay-
ment? The evidence suggests this to be the case, with the one exception of type 2 insulin-treated
diabetics, whose WTP values are very high but lack statistical significance. Also, whereas
non-diabetics and insulin-naive diabetics exhibit higher WTP values if financing is through
copayment, insulin-treated diabetics have higher values if financing is through insurance contri-
butions. This can be interpreted as a preference for financing through copayment on the part of
the non-affected non-diabetics and insulin-naive diabetics and through insurance of the part of
the affected insulin-treated diabetics. However, since even non-diabetics’ WTP is higher than
the actual treatment cost of insulin analogue regardless of mode of payment, its inclusion in the
German statutory health insurance GKV list of benefits can be justified.
These conclusions are subject to a number of reservations. First, the WTP estimates may be
biased upward because participants in the experiment may not be representative of the GKV
population. Indeed, the average net household income in the sample is below average, which may
result in a general dissatisfaction with the status quo. This might drive up WTP for alternative
treatment of diabetes as well. Second, in spite of differentiating between disease-specific groups,
there still may be hidden heterogeneity that could correlate with error terms, causing bias in
estimates. Finally, one may judge the cost-benefit standard adopted here as inappropriate. On
the one hand, benefits should be measured in terms of Quality Adjusted Life Years rather than
money should be measured according to some writers (see e.g. Williams & Cookson (2000),
Culyer (1990), or Drummond et al. (2005)). On the other hand, average WTP values neglect
distributional issues.
While these concerns may well be valid, they are unlikely to overthrow the major findings of this
study. First, there is clear evidence suggesting that not only the avoidance of hypoglycemia and
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weight gain but also attributes that typically are judged medically irrelevant such as no need
for preparation (swinging) and flexibility with regard to the timing of the injection are valued
attributes of insulin therapy. In addition, these attributes have positive WTP values among
diabetes patients and potential patients alike. Second, these valuations add up to total amounts
that exceed the marginal cost of the new drug, with the only exception of type 2 insulin-treated
diabetics whose WTP estimates, while sizable, cannot be distinguished from zero due to excess
heterogeneity. It is difficult to conceive of biases so strong and distributional weightings so
skewed to conclude that WTP values of GKV members likely fail to justify inclusion of this new
pharmaceutical in the benefit list.
Disclaimer
This study was paid for by Novo Nordisk Pharma GmbH. However, the authors independently
designed the experiment, and analyzed and interpreted the results without any influence from
the sponsor. The market research institute was selected and paid for by the authors and delivered
the data directly to them.
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